Başak DALBAYRAK, Mustafa Doğukan METİNER

Personalized Medicine: A Solution for Today and Tomorrow

Personalized medicine is a multidisciplinary area that contains several techniques to provide patients with more efficient, cheaper, and fewer side effects treatment strategies. In customized medicine, each patient is viewed individually in order to provide more specific and efficient treatment. Using liquid biopsy, pharmacogenetics, point-of-care-testing, multi-omicbased technologies, wearable technologies, organoids, and 3D printers are some of the strategies covered in this review. Omics technology is promising for data collection, and management is vital for health records to combine complete information in one single platform. 3D printer technologies give opportunities to produce multi-drug tablets with controlled and targeted drug release. Additionally, organoids are the other biomaterial approaches to mimic the tumoroid microenvironment to develop new treatment strategies. Increasing demand for personalized medicine affects the improvement scope of this technology; personalized medicine is a vital and urgent area to improve.

Keywords:

Personalized medicine, Liquid biopsy, Point-of-care-testing, Pharmacogenetic, Wearable devices biomaterials, organoids/spheroids,

PDF

___

1. Aguado BA, Grim JC, Rosales AM, Watson-Capps JJ, Anseth KS. Engineering precision biomaterials for personalized medicine. Sci Transl Med 2018;10(424). google scholar
2. Franssen FME, Alter P, Bar N, Benedikter BJ, Iurato S, Maier D, et al. Personalized medicine for patients with COPD: Where are we? Int J COPD 2019;14:1465-84. google scholar
3. Gilazieva Z, Ponomarev A, Rutland C, Rizvanov A, Solovyeva V. Promising applications of tumor spheroids and organoids for per-sonalized medicine. Cancers (Basel) 2020;12(10):1- 19. google scholar
4. Fröhlich H, Balling R, Beerenwinkel N, Kohlbacher O, Kumar S, Len-gauer T, et al. From hype to reality: Data science enabling person-alized medicine. BMC Med 2018;16(1):1-15. google scholar
5. Mathur S, Sutton J. Personalized medicine could transform health-care (Review). Biomed Reports 2017;7(1):3-5. google scholar
6. Vogenberg FR, Barash CI, Pursel M. Personalized medicine - Part 1: Evolution and development into theranostics. P T. 2010;35(10). google scholar
7. Papassotiropoulos A. The potential and limits of personalized medicine. 2012;1-10. google scholar
8. Dall’Era MA, Davies BJ, Eggener S. Active surveillance for prostate cancer. Transl Androl Urol 2018;7(2):195-6. google scholar
9. Sadee W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 2005;14(2):207-14. google scholar
10. Arciniegas Paspuel, O. G., Âlvarez Hernandez, S. R., Castro Morales, L. G., & Maldonado Gudino CW. Europe Precision Medicine Market. Graphical Research. 2021. p. 6. google scholar
11. Goetz LH, Schork NJ. Personalized medicine: motivation, challeng-es, and progress. Fertil Steril 2018;109(6):952-63. google scholar
12. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: Ameri-can society of clinical oncology and college of American patholo-gists joint review. J Clin Oncol 2018;36(16):1631-41. google scholar
13. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clin-ic — implementation issues and future challenges. Nat Rev Clin Oncol 2021;18(5):297-312. google scholar
14. Marrugo-Rarnurez J, Mir M, Samitier J. Blood-based cancer bio-markers in liquid biopsy: A promising non-invasive alternative to tissue biopsy. Int J Mol Sci 2018;19(10):1-21. google scholar
15. Hardingham JE. Detection of circulating tumor cells using lmmu-nobead-PCR. Clin Appl PCR 2003;2014:225-32. google scholar
16. Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabieres C, Janni W, et al. Clinical application of circulating tumor cells in breast cancer: Overview of the current interventional trials. Cancer Metastasis Rev 2013;32(1-2):179-88. google scholar
17. Torres S, Gonzalez Â, Cunquero Tomas AJ, Calabuig Farinas S, Fer-rero M, Mirda D, et al. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. Expert Rev Mol Diagn 2020;20(6):575-82. google scholar
18. Ferro M, La Civita E, Liotti A, Cennamo M, Tortora F, Buonerba C, et al. Liquid biopsy biomarkers in urine: A route towards molecular diagnosis and personalized medicine of bladder cancer. J Pers Med 2021;11(3):1-17. google scholar
19. Gadalla AAH, Friberg IM, Kift-Morgan A, Zhang J, Eberl M, Topley N, et al. Identification of clinical and urine biomarkers for uncom-plicated urinary tract infection using machine learning algorithms. Sci Rep 2019;9(1):1-11. google scholar
20. Lamb JR, Jennings LL, Gudmundsdottir V, Gudnason V, Emilsson V. It’s in Our Blood: A Glimpse of Personalized Medicine. Trends Mol Med 2021;27(1):20-30. google scholar
21. Schork NJ. Time for one-person trials.:3-5. google scholar
22. Mini E, Nobili S. Pharmacogenetics: Implementing personalized medicine. Clin Cases Miner Bone Metab 2009;6(1):17-24. google scholar
23. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Silent polymorphisms speak: How they affect pharmacogenomics and the treatment of cancer. Cancer Res 2007;67(20):9609-12. google scholar
24. Marsh S, Van Rooij T. Challenges of incorporating pharmacogenom-ics into clinical practice. Gastrointest Cancer Res 2009;3(5):206-7. google scholar
25. Ventola CL. The role of pharmacogenomic biomarkers in predict-ing and improving drug response. P T 2013;38(10):624-7. google scholar
26. FDA. Drugs Table of Pharmacogenomic Biomarkers in Drug Label-ing 2014;1-15. google scholar
27. Dere WH, Suto TS. The role of pharmacogenetics and pharmacog-enomics in improving translational medicine. Clin Cases Miner Bone Metab 2009;6(1):13-6. google scholar
28. John AS, P Price C. Existing and emerging technologies for point-of-care testing. Clin Biochem Rev 2014;35(3):155-67. google scholar
29. Nichols JH, Street C. Management of point-of-care testing. 1999;1-13. Avaible from: https://acutecaretesting.org/en/articles/man-agement-of-pointofcare-testing google scholar
30. Lewis K, Joyce-Nagata B, Gilmore Fite E. The Effect of time and tem-perature on blood glucose measurements. Home Healthc Nurse 1992;10(3):56-61. google scholar
31. Luppa PB, Müller C, Schlichtiger A, Schlebusch H. Point-of-care testing (POCT): Current techniques and future perspectives. TrAC -Trends Anal Chem 2011;30(6):887-98. google scholar
32. Bhardwaj V, Kapoor P, Irpachi K, Ladha S, Chowdhury U. Thailand Blood Gas Analyzer and Cardiac Biomarker Market Outlook to 2025 - Thailand’s growing number of heart disease patients with improving healthcare facilities will drive the industry growth in long term: Ken Research. Ann Card Anaesth 2017;20(1):67-71. google scholar
33. Çaltekin İ, Gökçen E, Albayrak L, Atik D, Savrun A, Kuşdoğan M, et al. Inflammatory markers and blood gas analysis in determining the severity of chronic obstructive pulmonary disease. Eur J Critic Care 2020;2(2):187-92. google scholar
34. Research K. Thailand blood gas analyzer and cardiac biomark-er market outlook to 2025 - thailand’s growing number of heart disease patients with improving healthcare facilities will drive the industry growth in long term: Ken Research. 2021; Available from: https://www.prnewswire.com/news-releases/ thailand-blood-gas-analyzer-and-cardiac- biomarker-market-outlook-to-2025---thailands-growing-number-of-heart-disease-patients-with-improving-healthcare-facilities-will-drive-the-in-dustry-growth-in-long- term-ken-res google scholar
35. de Oliveira Vilar Neto J, da Silva CA, Meneses GC, Pinto DV, Brito LC, da Cruz Fonseca SG, et al. Novel renal biomarkers show that cre-atine supplementation is safe: a double- blind, placebo-controlled randomized clinical trial. Toxicol Res (Camb) 2020;9(3):263-70. google scholar
36. Dorcely B, Katz K, Jagannathan R, Chiang SS, Oluwadare B, Gold-berg IJ, et al. Novel biomarkers for prediabetes, diabetes, and as-sociated complications. Diabetes, Metab Syndr Obes Targets Ther 2017;10: 345-61. google scholar
37. Memtsa M, Jurkovic D, Jauniaux ERM. Diagnostic biomarkers for predicting adverse early pregnancy outcomes: Scientific impact paper no. 58. BJOG An Int J Obstet Gynaecol 2019;126(3):e107-13. google scholar
38. Cho SI, Goldman MB, Ryan LM, Chen C, Damokosh AI, Christiani DC, et al. Reliability of serial urine HCG as a biomarker to detect early pregnancy loss. Hum Reprod 2002;17(4):1060-6. google scholar
39. Hwang H, Hwang BY, Bueno J. Biomarkers in infectious diseases. Dis Markers 2018;2018:2-3. google scholar
40. Zandstra J, Jongerius I, Kuijpers TW. Future biomarkers for infection and inflammation in febrile children. Front Immunol 2021;12:1-14. google scholar
41. Zermatten MG, Fraga M, Calderara DB, Aliotta A, Moradpour D, Al-berio L. Biomarkers of liver dysfunction correlate with a prothrom-botic and not with a prohaemorrhagic profile in patients with cir-rhosis. JHEP Reports 2020;2(4). google scholar
42. Nadkarni GN, Coca SG, Meisner A, Patel S, Kerr KF, Patel UD, et al. Urinalysis findings and urinary kidney injury biomarker concentra-tions. BMC Nephrol 2017;18(1):1-6. google scholar
43. Cirillo D, Valencia A. Big data analytics for personalized medicine. Curr Opin Biotechnol 2019;58:161-7. google scholar
44. Hassan M, Awan FM, Naz A, Enrique J, Alvarez O, Cernea A, et al. Innovations in genomics and big data analytics for personalized medicine and health care: A review. Int J Mol Sci 2022;23(9):4645. google scholar
45. Hulsen T, Jamuar SS, Moody AR, Karnes JH, Varga O, Hedensted S, et al. From big data to precision medicine. Front Med 2019;6:1-14. google scholar
46. Abul-Husn NS, Kenny EE. Personalized medicine and the power of electronic health records. Cell 2019;177(1):58-69. google scholar
47. Phillips KA, Deverka PA, Hooker GW, Douglas MP. Genetic test availability and spending: Where are we now? Where are we go-ing? Health Aff 2018;37(5):710-6. google scholar
48. Jacob M, Lopata AL, Dasouki M, Abdel Rahman AM. Metabolomics toward personalized medicine. Mass Spectrom Rev 2019;38(3):221-38. google scholar
49. Tan YJN, Yong WP, Kochhar JS, Khanolkar J, Yao X, Sun Y, et al. On-demand fully customizable drug tablets via 3D printing tech-nology for personalized medicine. J Control Release 2020;322:42-52. google scholar
50. Reza Soroushmehr SM, Najarian K. Transforming big data into computational models for personalized medicine and health care. Dialogues Clin Neurosci 2016;18(3):339-43. google scholar
51. Alrefaei AF, Hawsawi YM, Almaleki D, Alafif T, Alzahrani FA, Bakhre-bah MA. Genetic data sharing and artificial intelligence in the era of personalized medicine based on a cross- sectional analysis of the Saudi human genome program. Sci Rep 2022;12(1):1-10. google scholar
52. Guiot J, Vaidyanathan A, Deprez L, Zerka F, Danthine D, Frix AN, et al. A review in radiomics: Making personalized medicine a reality via routine imaging. Med Res Rev 2022;42(1):426-40. google scholar
53. Tamsin M. Wearable biosensor technologies. Int J Innov Sci Res 2015;13(2):697-703. google scholar
54. Yetisen AK, Martinez-Hurtado JL, Ünal B, Khademhosseini A, Butt H. Wearables in medicine. Adv Mater 2018;30(33):e1706910. google scholar
55. Dunn J, Runge R, Snyder M. Wearables and the medical revolution. Per Med 2018;15(5):429-48. google scholar
56. Izmailova ES, Wagner JA, Perakslis ED. Wearable devices in clinical trials: Hype and hypothesis. Clin Pharmacol Ther 2018;104(1):42-52. google scholar
57. Hoeben A, Joosten EAJ, van den Beuken-Van Everdingen MHJ. Per-sonalized medicine: Recent progress in cancer therapy. Cancers (Basel) 2021;13(2):1-3. google scholar
58. Takahashi T. Organoids for drug discovery and personalized medi-cine. Annu Rev Pharmacol Toxicol 2019;59:447-62. google scholar
59. Halfter K, Hoffmann O, Ditsch N, Ahne M, Arnold F, Paepke S, et al. Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids. J Transl Med 2016;14(1):1-14. google scholar
60. Vaz VM, Kumar L. 3D Printing as a promising tool in personalized medicine. AAPS PharmSciTech 2021;22(1):49. google scholar
61. Sharpton SR, Schnabl B, Knight R, Loomba R. Current concepts, opportunities, and challenges of gut microbiome-based person-alized medicine in nonalcoholic fatty liver disease. Cell Metab 2021;33(1):21-32. google scholar